Prasugrel Hydrochloride
FDA-approved product (tablet, oral), marketed as Effient, Prasugrel, Prasugrel Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute coronary syndrome
- Hemorrhage
- Intermediate coronary syndrome
- Myocardial infarction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Platelet aggregation inhibitors excl. heparin
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Prasugrel Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Prasugrel/Clopidogrel Maintenance Dose Washout Study
NCT01014624 · start 2010-02
Registered record
- Registry ID
- NCT01014624
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-02
- Completion
- 2010-06
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionPrasugrel; ClopidogrelPhasePhase 4Registry statusCompletedCYPRESS - CYPHER for Evaluating Sustained Safety
NCT00954707 · start 2009-08
Registered record
- Registry ID
- NCT00954707
- Conditions
- Coronary Artery Disease
- Interventions
- Clopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & Aspirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2009-08
- Completion
- 2016-03
- Enrolment
- 2,509
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionClopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & AspirinPhasePhase 4Registry statusUnknownA Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
NCT00699998 · start 2008-06
Registered record
- Registry ID
- NCT00699998
- Conditions
- Acute Coronary Syndrome
- Interventions
- Clopidogrel; Prasugrel; Commercially-available Aspirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-06
- Completion
- 2012-04
- Enrolment
- 9,326
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionClopidogrel; Prasugrel; Commercially-available AspirinPhasePhase 3Registry statusCompletedThird Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
NCT00642174 · start 2008-04
Registered record
- Registry ID
- NCT00642174
- Conditions
- Diabetes Mellitus; Coronary Artery Disease
- Interventions
- prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-04
- Completion
- 2009-01
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus; Coronary Artery DiseaseInterventionprasugrel; ClopidogrelPhasePhase 2Registry statusCompletedThe Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
NCT00385944 · start 2007-03
Registered record
- Registry ID
- NCT00385944
- Conditions
- Acute Coronary Syndrome
- Interventions
- Prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2007-10
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionPrasugrel; ClopidogrelPhasePhase 2Registry statusCompleted